A new analysis using data from Kite Pharma’s Zuma-1 and Zuma-7 trials linked patient genetics to CAR-T toxicity risk in Yescarta (axi-cel). Published in Science Immunology, the study highlighted mutations in STXBP2 in Zuma-1 patients that corresponded with toxicity after treatment.